The c-Myc protein is diversely involved in normal cellular function, and its deregulation has been implicated in several cancers. Therefore, c-Myc is a validated target for anti-cancer therapeutics. Here, we developed a monoclonal antibody specific to an epitope involved in the protein–protein interaction and DNA binding of c-Myc. We selected two candidate epitopes based on the antigenicity prediction and 3-D structure of c-Myc and successfully obtained a c-Myc-specific monoclonal IgG2a antibody clone. Based on the immunoprecipitation assay, the antibody recognized overexpressed c-Myc as well as endogenously expressed c-Myc in cell lines. The antibody co-immunoprecipitated Max showing that the antibody can recognize the c-Myc-Max heterodimer in solution. The results from the ELISA-based DNA binding assay revealed that treatment with the monoclonal antibody inhibits the binding activity of c-Myc. Therefore, we suggest that our anti-c-Myc monoclonal antibody can be used as a starting material for the development of an anti-cancer drug targeting c-Myc.
B cell epitope MAb Max C-Myc
This is a preview of subscription content, log in to check access.
This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning in the Republic of Korea (NRF-2015R1A2A2A01007209, 2014M3C1A3051473, 2016M3A9B6916708, 2009-0093812). Byoung Kwon Park was supported by the Hallym University Postdoctoral Fellowship Program of 2017 (HLM-PF-2017-0001).
Compliance with Ethical Standards
Conflict of interest
Byoung Kwon Park, Avishekh Gautam, Sony Maharjan, Su In Lee, Younghee Lee and Hyung-Joo Kwon confirm that this article content has no conflicts of interest.
Research Involving Human and Animal Rights
All institutional and national guidelines for the care and use of laboratory animals were followed. All procedures performed in studies involving animals were approved by the institutional animal ethical committee. This article does not include any studies using human subjects.
The article does not contain any studies in patients by any of the authors.
Avignolo C, Bagnasco L, Biasotti B et al (2008) Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 22(4):1237–1245CrossRefGoogle Scholar
Berg T (2011) Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol 348:139–149Google Scholar
Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251(4998):1211–1217CrossRefGoogle Scholar
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121–1124CrossRefGoogle Scholar
Conacci-Sorrell M, McFerrin L, Eisenman RN (2014) An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4(1):a014357CrossRefGoogle Scholar
Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19(1):1–11CrossRefGoogle Scholar
Guillard S, Minter RR, Jackson RH (2015) Engineering therapeutic proteins for cell entry: the natural approach. Trends Biotechnol 33(3):163–171CrossRefGoogle Scholar
Hönnemann J, Sanz-Moreno A, Wolf E, Eilers M, Elsässer HP (2012) Miz1 is a critical repressor of cdkn1a during skin tumorigenesis. PLoS ONE 7(4):e34885CrossRefGoogle Scholar
Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV (2015) MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43:11–21CrossRefGoogle Scholar
Kiessling A, Sperl B, Hollis A, Eick D, Berg T (2006) Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 13(7):745–751CrossRefGoogle Scholar
Kim D, Kwon S, Rhee JW et al (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12:29CrossRefGoogle Scholar
Kwon S, Choi KC, Kim YE et al (2014) Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res 74(14):3844–3856CrossRefGoogle Scholar
Marschall AL, Zhang C, Frenzel A et al (2014) Delivery of antibodies to the cytosol: debunking the myths. MAbs 6(4):943–956CrossRefGoogle Scholar
Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193–205CrossRefGoogle Scholar
Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: marvelously complex. Adv Cancer Res 84:81–154CrossRefGoogle Scholar
Park BK, Choi SH, Kim YE et al (2015) Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34(2):101–109CrossRefGoogle Scholar
Park BK, Lee SI, Lee Y et al (2016) Effect of a monoclonal antibody against relaxin-2 on cancer cell growth inhibition. Appl Biol Chem 59(5):739–746CrossRefGoogle Scholar
Sakamuro D, Prendergast GC (1999) New Myc-interacting proteins: a second Myc network emerges. Oncogene 18(19):2942–2954CrossRefGoogle Scholar
Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287CrossRefGoogle Scholar
Sheiness D, Bishop JM (1979) DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 31(2):514–521Google Scholar
Sohn WJ, Kim D, Lee KW et al (2007) Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol Immunol 44(13):3273–3282CrossRefGoogle Scholar
Soucek L, Jucker R, Panacchia L et al (2002) Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62(12):3507–3510Google Scholar